American and European regulators have given Celgene Corporation the OK to begin marketing its top-selling myeloma drug Revlimid as a first-line therapy.
from RSSMix.com Mix ID 7863557 http://ift.tt/1LMxsPH via binary app
from RSSMix.com Mix ID 7863557 http://ift.tt/1LMxsPH via binary app
No comments:
Post a Comment